Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 334-344

  Rosen, Sydney ^a,b,c   Long, Lawrence ^b   Fox, Matthew ^a,b   Sanne, Ian ^b  

^a Center for International Health and Development   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Cost and cost effectiveness; South Africa; Stavudine; Tenofovir; Toxicities

Indexed keywords

EFAVIRENZ; LAMIVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SOUTH AFRICA; UNSPECIFIED SIDE EFFECT; ADULT; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; ECONOMICS;

ADENINE; ADULT; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; HUMANS; MODELS, BIOLOGICAL; PHOSPHONIC ACIDS; QUALITY OF LIFE; SOUTH AFRICA; STAVUDINE;

EID: 47049121281     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817ae5ef     Document Type: Article

References (29)

1. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007;21(Suppl 4):S89-S95.
2. Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007; 45:1093-1101.
3. Wong EB, Murdoch D, Wing J, et al. High Rates of Non-Fatal Toxicities in a 24-Month Cohort Receiving Publicly Funded HAART in South Africa: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, CA, 25-28 February 2007. Abstract 795.
4. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:304-310.
5. Toure S, Seyler C, Messou E, et al. Main reasons of modification of the first-line antiretroviral regimen in adult patients who initiated HAART in the International Family Health Initiative (ACONDA/ISPED/EGPAF) in Abidjan, Cote d'Ivoire. Paper presented at: 3rd HIV/AIDS Implementers' Meeting; June 16-19, 2007; Kigali, Rwanda. Abstract 1215.
6. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007;45: 254-260.
7. Osler M, Stead D, Rebe K, et al. Severe Hyperlactatemia Complicating ART With Stavudine First-Line Therapy in South Africa: Incidence, Risk Factors, and Outcomes: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, CA, 25-28 February 2007. Abstract 792.
8. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007;46:318-322.
9. Mutimura E, Stewart A, Rheeder P, et al. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:451-455.
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
11. Kiguba R, Byakika-Tusiime J, Karamagi C, et al. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr. 2007;45:218-223.
12. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4:e298.
13. Aspen Pharmacare. Launch of Viread and Truvada. Press release. April 2007.
14. Alcorn K. First-line treatment choices proving challenging for African ART programmes. Aidsmap News. June 27, 2007.
15. Alcorn K. CROI: high burden of side-effects from d4T leads to WHO dose reduction recommendation. Aidsmap News. March 21, 2007.
16. Smith CJ, Olsen CH, Mocroft A, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS. 2008;22:47-56.
17. Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, England:Oxford University Press; 2006.
18. Drummond MF, Sculpher M, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programme. 3rd ed. Oxford, England: Oxford University Press; 2005.
19. Harling G, Wood R. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr. 2007;45:348-354.
20. Wolf LL, Ricketts P, Freedberg K, et al. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr. 2007;46:463-471.
21. Amoroso A, Sheneberger R, Edozien A, et al. ART-Associated Toxicities Leading to a Switch in Medication: Experience in Uganda, Kenya, and Zambia: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, CA, 25-28 February 2007. Abstract 789.
22. Thaczuk D. Is tenofovir causing kidney problems? Aidsmap News. March 13, 2007. Available at: www.aidsmap.com/en/news/B19ACD5D-29AC-410F-9AB9. Accessed November 12, 2007.
23. World Bank. South Africa Data Profile, World Development Indicators Database, April 2007. Washington, DC: The World Bank; 2007.
24. World Health Organisation. A Summary Report From the Global Price Reporting Mechanism on Antiretroviral Drugs, October 2007. Geneva, Switzerland: World Health Organization; 2007. Available at: http://www.who.int/ hiv/amds/GPRMsummaryReportOct07.pdf. Accessed March 28, 2008.
25. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44:456-462.
26. Rapoport J, Teres D, Zhao Y, et al. Length of stay data as a guide to hospital economic performance for ICU patients. Med Care. 2003;41: 386-397.
27. Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care. 2004;27:901-907.
28. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007;45:1062-1070.
29. Nyman JA, Barleen NA, Dowd BE, et al. Quality of life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care. 2007;45:618-628.